Date Announced: Join us on October 17, 2024 in New York City for The Michael J. Fox Foundation's 16th annual Parkinson's Disease Therapeutics Conference. Join over 300 research and business development professionals from both academia and industry for the world's only conference exclusively focused on Parkinson's disease drug development. Use promo code EB2024 for an early bird special (ends July 19). Learn more and register today: https://bit.ly/3x6WUE5
The Michael J. Fox Foundation for Parkinson's Research’s Post
More Relevant Posts
-
Identity of company ‐-------------------------------- Therasid Bioscience is dedicated to NASH therapeutics, so all the pipelines of company are addressed to NASH indication. Therasid deal with steatosis, inflammation and fibrosis as each representative disease activities of NASH. Our mid-term goal is treating NASH-fibrosis by a direct fibrosis resolving mechanism of actions. Therasid's ultimate goals in this field are investigation of current pathogenesis and discoveries of new pathogenesis for the cure of NASH.
To view or add a comment, sign in
-
On 15 Nov, join the webinar “Where do biosimilars fit into the Cancer treatment puzzle?” to get an overview of the benefits that #BiosimilarMedicines can provide to #CancerCare and join #GlobalBiosimilarsWeek #GBW23 🧪
Global Biosimilars Week 2023
https://www.globalbiosimilarsweek.org/2023
To view or add a comment, sign in
-
October 18 Breaking New Ground in Cancer, Immune Disorders and Infection Register here! https://lnkd.in/gCT3XnPg We'll highlight the state-of-the-art research taking place at Rosalind Franklin University of Medicine and Science & detail the novel approaches for diagnosing and treating disease. #ChicagoBiotech #Biotech #lifesciences
Biomedical Innovation Day
rosalindfranklin.edu
To view or add a comment, sign in
-
Exciting to see several positive developments in Biotech this morning: 1️⃣ Immunovant Announces positive initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results. 2️⃣ Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis. 3️⃣ Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome. 4️⃣ Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases. Immunovant PR: https://lnkd.in/eeD6QkCF Pliant PR: https://lnkd.in/eZcQF-2z Soleno PR: https://lnkd.in/e-EZ9D3i Alfasigma/Intercept PR: https://lnkd.in/e3Wj6ybm
To view or add a comment, sign in
-
[Clinical Trials] Vicore Pharma AB's phase 2a trial of Digital therapy Almee shows a 2.7-point improvement in anxiety symptoms in Anxiety with Pulmonary Fibrosis https://lnkd.in/gY3DpKM3 Soligenix, Inc.'s phase 2a trial of SGX302 demonstrates positive outcomes in treating psoriasis https://lnkd.in/g5S5ce7i Theravance Biopharma US, Inc.'s phase 4 study of YUPELRI reveals no significant difference from Spiriva HandiHaler in COPD https://lnkd.in/gbe-e-6a Jiangsu Simcere Pharmaceutical's phase 3 trial of BD0801 met primary endpoint in ovarian cancer, fallopian tube cancer, and peritoneal cancer patients https://lnkd.in/gRcDwvt5 Stayble Therapeutics' phase 2b trial of STA363 for chronic disc-related back pain did not achieve primary objective https://lnkd.in/g9jTpNY7
Vicore Pharma AB's phase 2a trial of Digital therapy Almee shows a 2.7-point improvement in anxiety symptoms in Anxiety with Pulmonary Fibrosis
efortless.bio
To view or add a comment, sign in
-
********EARLY BIRD ALERT*********** It is early bird week for the 4th B&T Cell Mediated Autoimmune Disease Drug Development Summit! Looking achieve more targeted B cell modulation and depletion in autoimmunity? Attend the 4th B&T Cell Mediated Autoimmune Disease Drug Development to distinguish pathogenic B cells, move beyond lineage depleting strategies, overcome tissue specific delivery challenges and achieve broader efficacy in wider autoimmune patient populations. Join the likes of Namita Gandhi, Andreas Radbruch, Shawn Rose MD, PhD, Carrie Saulsbery, Michael Howell, Kira Rubtsova, Taylor L. Reynolds, Navin Rao, Ph.D., Mark Selby, Jim Paulson, David Rothstein, Sheng Xiao to help bring more targeted tissue and antigen specific therapies to patients in need. This is your last chance to register and take advantage of our largest discounts which end this Friday, September 15. Click here to learn more information: https://ter.li/ot42ia #drugdevelopment #drugdiscovery #autoimmunity
Home – 4th B & T Cell-Mediated Autoimmune Disease Drug Development | Boston, MA
b-and-t-cell-for-autoimmune.com
To view or add a comment, sign in
-
Don't forget to join Vigeo Therapeutics COO Dr. Jing Watnick updating the Fifth Annual Glioblastoma Drug Development Summit TODAY at 1:30 PM EDT today (March 28) in Boston, MA. Dr. Watnick will give an overview of #VT1021 in our Ph1/2 program in GBM as well as the future use of #VT1021 in attacking the roots of Neuro-inflammatory disease #GBM #Glioblastoma #NeurodegenerativeDisease #NeuroInflammatoryDisease #GBMSummit
To view or add a comment, sign in
-
See the link below to register to participate in this important discussion toward mitigating cancer drug shortages. Join this 2-hour virtual meeting on September 26th at 9 am ET. #supplychainresilience #patientsafety US Pharmacopeia #drugshortages #healthcare
Please join the American Cancer Society (ACS), American Cancer Society Cancer Action Network (ACS CAN) and the USP Convention for a timely and impactful discussion with key thought leaders and experts on the pharmaceutical supply chain. Add your voice and perspective as we identify the most impactful interventions for policymakers, regulators, industry, healthcare, and providers to address the urgent issue of cancer drug shortages on behalf of patients nationwide. When: Tuesday, September 26th, 2023, 9:00-11:00 ET Please register for this virtual event and share this invitation with colleagues who would benefit from and contribute to this important dialogue. https://ow.ly/spqJ50PGr1u #drugshortage #supplychain
To view or add a comment, sign in
-
-
🙌 Exciting news for liver disease, as Gilead Sciences acquires CymaBay Therapeutics! The acquisition gives Gilead ownership of Seladelpar, a drug to treat Primary Biliary Cholangitis (PBC), a disease which affects the bile ducts that run through the liver. The therapy is currently under review by the FDA, following a recent Phase III RESPONSE trial, which showed statistically significant results versus a placebo. As a fellow therapy developer in the liver disease space, this news is heartening – demonstrating that persistence, adaptability, and focused execution are key to advancing novel medicines for patients. Read more about the acquisition at STAT ⬇️ #biotech #genomics #LiverDisease
Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease
https://www.statnews.com
To view or add a comment, sign in
-
Innovation Engagement and Science Communications Expert, constantly connecting across science, arts, engineering, humanities, and qualities of life.
Join me and US Pharmacopeia colleagues to for a discussion on addressing tragic shortages of cancer drugs - please share with your networks cc Ana Tergas Guru Madhavan Jitesh Soares Joshua LaBaer
Please join the American Cancer Society (ACS), American Cancer Society Cancer Action Network (ACS CAN) and the USP Convention for a timely and impactful discussion with key thought leaders and experts on the pharmaceutical supply chain. Add your voice and perspective as we identify the most impactful interventions for policymakers, regulators, industry, healthcare, and providers to address the urgent issue of cancer drug shortages on behalf of patients nationwide. When: Tuesday, September 26th, 2023, 9:00-11:00 ET Please register for this virtual event and share this invitation with colleagues who would benefit from and contribute to this important dialogue. https://ow.ly/spqJ50PGr1u #drugshortage #supplychain
To view or add a comment, sign in
-